港股医药股早盘走强，信达生物、药明康德涨超2%。 每日经济新闻 受盘面影响，多只港股医药相关ETF涨约2%。 | 代码 | 类型 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 520880 | 跨 港股通创新药ETF T+0 | 1.326 | 0.059 | 4.66% | | 159557 | 跨 恒生医疗ETF嘉实 T+0 | 1.803 | 0.042 | 2.39% | | 159718 | 覧 港股医药ETF T+0 | 1.067 | 0.023 | 2.20% | | 159366 | 跨 港股医疗ETF T+O | 1.571 | 0.037 | 2.41% | | 159615 | 跨 恒生生物科技ETF T+0 | 1.350 | 0.025 | 1.89% | | 159776 | 跨 港股通医药ETF T+0 | 1.417 | 0.027 | 1.94% | | 513200 | 跨 港股通医药ETF T+0 | 1.263 | 0.024 | 1.94% | 有券商表示，我国创新药研发数量已居全球第一，且部分领域 ...

Group 1 - The innovation drug sector is experiencing a strong positive sentiment, with the Hong Kong pharmaceutical ETF (159718.SZ) rising by 2.01%, marking a six-day consecutive increase and an annual gain of nearly 84%, reaching a new net value high [1] - Key stocks in the sector, such as MicroPort Medical (00853), Innovent Biologics (01801), and WuXi AppTec (02359), have shown significant price increases, indicating robust market performance [1] - The overall crowding level in the pharmaceutical sector is at a historical average, with innovation drugs being relatively crowded, while the CXO sector shows lower crowding; the CXO sector is expected to recover strongly due to favorable conditions such as potential interest rate cuts by the Federal Reserve and improved investment environment in pharmaceuticals [1] Group 2 - The Hong Kong pharmaceutical ETF focuses on 18A biotech companies, including key players like BeiGene, WuXi Biologics, and CSPC Pharmaceutical, benefiting from global innovation drug development [2] - The combination of policy benefits, international expansion, and profit realization is driving the revaluation of Hong Kong pharmaceutical stocks, suggesting a positive outlook for the Hong Kong pharmaceutical ETF (159718.SZ) and its associated funds [2]

Group 1 - Several securities firms, including CITIC Securities and Guosen Securities, have quickly launched trading permissions for the new Sci-Tech Growth Board, indicating high market interest in this new segment [1] - Investors need to meet a threshold of 500,000 yuan in assets and have two years of investment experience to participate, which helps filter qualified investors and manage risks [1] - The introduction of the Sci-Tech Growth Board enhances the multi-tiered capital market structure, providing financing channels for tech innovation companies, which is expected to boost overall market vitality and innovation momentum in the long term [1] Group 2 - On July 29, Founder Securities announced that its major shareholder, China Cinda Asset Management, did not execute its planned share reduction, which is seen as a positive signal for the company's long-term value [2] - The unchanged shareholding of China Cinda, which holds 593 million shares (7.2% of total shares), may help stabilize market sentiment and alleviate investor concerns about share dilution [2] - This situation is likely to support the brokerage sector and enhance confidence in financial stocks, contributing to market stability [2] Group 3 - In July, over 900 billion yuan worth of new funds were issued, indicating a recovery in market confidence [3] - The increase in stock and bond fund shares, driven by the equity market and innovative products like the Sci-Tech Bond ETF, reflects a growing risk appetite among investors [3] - The decline in mixed fund shares suggests a preference for clearer directional investments, which may lead to increased activity in related sectors and improved market liquidity [3] Group 4 - Seven ETFs have achieved "doubling" performance this year, with the top performer, Huatai-PB Hang Seng Innovation Drug ETF, showing a 107.67% return [4] - The strong performance of Hong Kong innovation drug ETFs highlights the robust market interest in the innovative drug sector, potentially attracting more capital into the healthcare segment [4] - Continued advancements in innovative drug research and supportive policies are key drivers for the pharmaceutical industry, with high-performing ETFs likely to enhance investor risk appetite [4]

创新药巨头，释放积极信号！ 另外，7月28日晚间，药明康德披露了2025年半年度报告。报告显示，公司上半年实现营业收入207.99亿元，同比增长20.64%；实现归母净利润85.61亿 元，同比增长101.92%。公司同时发布2025年中期利润分配方案，拟向全体股东每10股派发现金红利3.5元（含税）。 7月29日晚间，药明康德（603259）公告，拟将回购股份价格上限由不超过90.72元/股（含）调整为不超过114.15元/股（含）。截至当天收盘时，药明康 德股价上涨7.72%报98.69元/股，总市值超过2800亿元。 | | 药明康德 | | | | --- | --- | --- | --- | | | 603259 融 | | | | 98.69 | 高 99.76 换手 3.78% | | 量 94.01万 | | 低 90.70 | | 市值 2834.59亿 | 金额 90.14亿 | | 7.07 7.72% | 开 93.45 | 流通 2452.59亿 | 市盈™ 20.58 | | 日线 M5:90.05 M10:85.82 M20:79.29 M30:75.11 | | | ◎ 设置 ...

Core Insights - Fosun Pharma has signed a licensing agreement with NeuCo for the development and commercialization of AR1001, a small molecule oral drug aimed at delaying the progression of Alzheimer's disease [1][2][3] - The company plans to invest up to 150 million yuan in this collaboration, which includes an upfront payment of 40 million yuan and milestone payments based on regulatory progress [2][3] - Fosun Pharma's R&D investment for 2024 is projected to reach 5.554 billion yuan, enhancing its product pipeline in the central nervous system field [1][3] Financial Performance - In 2024, Fosun Pharma achieved a revenue of 41.07 billion yuan and a net profit of 2.77 billion yuan, with a significant increase in cash flow from operating activities [5][6] - For Q1 2025, the company reported a net profit of 765 million yuan, a year-on-year increase of 25.42%, despite a revenue decline of 7.26% [5] - The pharmaceutical segment remains a key pillar, contributing 28.92 billion yuan, accounting for 70.43% of total revenue in 2024 [5] Global Expansion - Fosun Pharma's overseas revenue reached 11.297 billion yuan in 2024, representing 27.51% of total revenue, with an 8.93% year-on-year growth [5][6] - The company has established a significant presence in international markets, including the US, Europe, Africa, India, and Southeast Asia, with over 1,000 personnel in its overseas commercialization team [5][6] Asset Growth - The total assets of Fosun Pharma increased to 118 billion yuan by the end of Q1 2025, marking a historical high and a 3.78% year-on-year growth [6] - From 2020 to 2024, the company's total assets grew from 83.69 billion yuan to 117.5 billion yuan, reflecting a 40.4% increase during this period [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，公司在研产品斯乐韦米单抗注射液2岁至18岁以下儿童和青少年疑似狂 犬病病毒暴露后的被动免疫适应症的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 药品名称：斯乐韦米单抗注射液 申请事项：境内生产药品注册临床试验 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSL2500414 适应症：2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，斯乐韦米单抗注射液临床试验申 请符合药品注册的有关要求，同意本品开展2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动 免疫适应症的临床试验。 重庆智翔金泰生物制药股份有限公司董事会 2025年7月30日 二、药品其他相关情况 斯乐韦米单抗注射液是一款由公司自主研发的重组全人源抗狂犬病 ...

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, achieving a revenue of 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% from the previous year [2] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [2] Financial Performance - Revenue for the first half of 2025 reached 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [2] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [2] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase from the previous year [2] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, representing a 23.97% increase year-on-year [2] - There are currently 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for certain in-development drugs [3] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its Oxycodone tablets [3] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical trials and is set to enter Phase III trials [3] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotech, has successfully completed Phase I clinical trials in the U.S. and is moving to Phase II trials [3]

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [1] Financial Performance - Revenue for the first half of 2025 was 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, a 10.33% increase year-on-year [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, which is a 23.97% increase compared to the previous year [1] - There are currently 17 innovative drug projects under development, including 1 completed Phase III clinical study and 2 completed Phase II studies [2] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for some of its drug projects [2] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its oxazepam tablet product [2] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical research and is about to enter Phase III [2] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotechnology, has successfully completed Phase I clinical research in the U.S. and is set to enter Phase II [2]

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of its product, Sileweimi Monoclonal Antibody Injection, aimed at passive immunity for children and adolescents aged 2 to 18 suspected of rabies virus exposure [1][2]. Group 1: Drug Information - The drug Sileweimi Monoclonal Antibody Injection is a recombinant fully human bispecific antibody targeting the rabies virus (Rabies Virus, RABV) [2]. - It is classified as a Class 1 therapeutic biological product, with its action target being the glycoprotein (G protein) of RABV [2]. - The drug employs scFv+Fab structure and KIH technology to address heavy chain mismatch issues, and scFv fusion technology to resolve light chain mismatch issues [2]. - It is the world's first bispecific antibody for passive immunity against rabies, designed to ensure effectiveness against different strains or genotypes of the virus [2]. Group 2: Clinical Trial Approval - The clinical trial application for Sileweimi Monoclonal Antibody Injection has been approved for the indication of passive immunity in children and adolescents aged 2 to 18 suspected of rabies virus exposure [1][2]. - The approval is in accordance with the relevant requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 3: Market Context - As of the announcement date, Sileweimi Monoclonal Antibody Injection is under review for new drug marketing application for adult passive immunity against suspected rabies virus exposure [2]. - Currently, only two rabies virus antibody drugs have been approved for marketing in China [2].

证券代码：688443 证券简称：智翔金泰 公告编号：2025-029 重庆智翔金泰生物制药股份有限公司 自愿披露关于斯乐韦米单抗注射液获得药物临床试 药品名称：斯乐韦米单抗注射液 申请事项：境内生产药品注册临床试验 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSL2500414 适应症：2 岁至 18 岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，斯乐 韦米单抗注射液临床试验申请符合药品注册的有关要求，同意本品开展 2 岁至 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家 药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品斯乐韦 米单抗注射液 2 岁至 18 岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 适应症的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 斯乐韦米单抗注射液为 scFv+Fab 结构的双特异性抗体，使用 KIH ...